A value-based healthcare model for initiating and switching psoriasis therapies — Results from the prospective multicentre IMPROVE study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background: Little is known about the therapeutic benefits of a value-based healthcare model compared to a traditional activity-based incentive model in psoriasis (PsO). Objectives: This prospective non-interventional study evaluated an outcome-based, patient-centred management model for patients with PsO. Methods: In total, 49 patients with a Psoriasis Area and Severity Index (PASI) ≥3 who were starting or switching between treatments were included. Patients were assessed at baseline, 3 and 9 months. The patient benefit index (PBI) was calculated using predefined questionnaires. An expected PBI was calculated and adjusted for risk factors known to complicate treatment, that is overweight and smoking. The model remunerated the department on whether the observed PBI exceeded the expected PBI to incentivize over-performance. Results: In total, 40 patients (80%) completed all three visits; 32.7% were smokers and 73.5% were overweight. Mean PASI at baseline was 11.5 (SD 9.1); PASI improved significantly from baseline through 3 months: mean reduction, 8.0 (SD 9.2), p < 0.001 and was maintained until 9 months: mean further reduction, 0.1 (SD 3.3), p = 0.893. The mean PBI was 2.5 (SD 1.3) and 2.8 (SD 1.1) at 3 and 9 months, respectively. A PBI ≥1 was achieved by 87.8% at 3 and 95.1% at 9 months. Overall, the department was remunerated a mean 2721.1 DKK (SD 4472.8) per patient. In subgroup analysis, the department was remunerated a mean of, respectively, 2428.6 (SD 5089.5), 2636.6 (SD 4471.3) and 3196.5 (SD 4497.1) DKK for patients with none, 1 or 2 risk factors, that is smoking or/and overweight. Conclusions: The model evaluated herein is the first value-based model to calculate remuneration from patient reported outcomes and showed to successfully predict the expected PBI and remunerate treatment based on whether the expected treatment goal was met or exceeded. This can be utilized in the patient-centred management of PsO.

TidsskriftJournal of the European Academy of Dermatology and Venereology
Udgave nummer5
Sider (fra-til)844-850
Antal sider7
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
We are grateful for the excellent technical support from Copenhagen Economics in building the financial management model. This work was supported by Novartis Healthcare A/S.

Publisher Copyright:
© 2023 European Academy of Dermatology and Venereology.

ID: 377450332